Alnylam Showcases Advanced RNAi Therapy Data for Heart Failure at ESC Congress

Biotech firm Alnylam presented new clinical findings at the European Society of Cardiology 2026 conference, highlighting the efficacy of its RNA interference drugs in treating transthyretin amyloid cardiomyopathy.

30 Aug, 13:12 — 30 Aug, 13:12

Post Share

Sources

Showing 1 of 1 sources

morningstar1d ago

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings - Morningstar

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings Morningstar

Read full article →

Alnylam Showcases Advanced RNAi Therapy Data for Heart Failure at ESC Congress

Sources

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings - Morningstar

Related Stories

Prediction Platform Kalshi Bans Former Congressman George Santos for Life

U.S. Treasury Yields Surge as Fed Official Signals Support for Rate Hike

Dell Stock Gains Investor Focus Ahead of September Earnings Report

Sony and Warner Music Sue Anthropic Over AI Training Copyright Claims